Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Université du Québec à Montréal

$25,000.00

Development of biophysical assays for fragment-based lead discovery strategies

EF 2017-18

Résumé
NMX Research and Solutions (NMX) is a Canadian translational research organization that providesdevelopment for drug discovery, including medicinal chemistry for leads and biophysical screening for hits.The main biophysical strategies of NMX is nuclear magnetic resonance (NMR), which provides atomic-levelinformation about compound solution properties and interactions with target biomolecules. Over the last years,NMX has developed a unique toolbox of NMR strategies to ensure delivery of quality hits and leads. TheseNMR-based integrated strategies for ligand screening for drug discovery now need to be supported withstate-of-the-art biophysical techniques. In this context, NMX has contacted Dr. Steve Bourgault to initiate acollaboration in order to support their innovative NMR methods for quantitative determination of smallmolecule binding affinity and binding kinetics. The analytical biochemistry laboratory of Dr. Bourgault atUQ?M has developed over the last years an expertise in the biophysical analysis of biomolecular interactions,including isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR).In this project, we will develop SPR and ITC strategies in parallel with NMR-based fragment-based leaddiscovery strategies through the screening of small molecules to identify ligands of galectin-7.SPR and ITC are state-of-the-art techniques for studying molecular interactions and for measuring bindingaffinity (Kd). However, the screening of the binding of low-molecular weight compounds, as used infragment-based lead discovery strategies, is very challenging and requires innovative techniques and manyrounds of optimisation. Moreover, many drug targets self-assemble into oligomeric states (dimer, tetramer) insolution, as for galectin-7. This makes any attempts to correlate the results obtained from different biophysicalmethods all but trivial. Using our expertise in the characterization of molecular interactions, we will supportNMX in the development of their unique NMR-based screening platform and we will gain a unique andunprecedented direct correlation between these biophysical techniques.
Programme
Engage Grants Program
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
521180-2017
Name nom
Bourgault, Steve
Department département
Chimie
Organization id
57
Institution établissement
Université du Québec à Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
1
Nb partie
1
Application title
Development of biophysical assays for fragment-based lead discovery strategies
Keyword
NSERC
Application summary
NMX Research and Solutions (NMX) is a Canadian translational research organization that providesdevelopment for drug discovery, including medicinal chemistry for leads and biophysical screening for hits.The main biophysical strategies of NMX is nuclear magnetic resonance (NMR), which provides atomic-levelinformation about compound solution properties and interactions with target biomolecules. Over the last years,NMX has developed a unique toolbox of NMR strategies to ensure delivery of quality hits and leads. TheseNMR-based integrated strategies for ligand screening for drug discovery now need to be supported withstate-of-the-art biophysical techniques. In this context, NMX has contacted Dr. Steve Bourgault to initiate acollaboration in order to support their innovative NMR methods for quantitative determination of smallmolecule binding affinity and binding kinetics. The analytical biochemistry laboratory of Dr. Bourgault atUQ?M has developed over the last years an expertise in the biophysical analysis of biomolecular interactions,including isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR).In this project, we will develop SPR and ITC strategies in parallel with NMR-based fragment-based leaddiscovery strategies through the screening of small molecules to identify ligands of galectin-7.SPR and ITC are state-of-the-art techniques for studying molecular interactions and for measuring bindingaffinity (Kd). However, the screening of the binding of low-molecular weight compounds, as used infragment-based lead discovery strategies, is very challenging and requires innovative techniques and manyrounds of optimisation. Moreover, many drug targets self-assemble into oligomeric states (dimer, tetramer) insolution, as for galectin-7. This makes any attempts to correlate the results obtained from different biophysicalmethods all but trivial. Using our expertise in the characterization of molecular interactions, we will supportNMX in the development of their unique NMR-based screening platform and we will gain a unique andunprecedented direct correlation between these biophysical techniques.